Technical Data
F0019-56W
FAK (Focal Adhesion Associated Protein Tyrosine Kinase, BC3)
Description:
Focal adhesion kinase (FAK) is a non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis (1). FAK is composed of a central catalytic domain flanked by large N- and C-terminal regions. FAK is activated by phosphorylation at tyrosine 397 in response to integrin clustering which can be induced by cell adhesion or antibody cross-linking or via G-protein-coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid (2-3). FAK expression is upregulated in various tumors (4). Increased FAK expression has been correlated with the enhanced motility and invasiveness of human tumor cells, as well as with promoting increased cell proliferation (5).

Applications:
Suitable for use in Western Blot, Immunoprecipitation, Immunohistochemistry and Immunocytochemistry. Other applications not tested.

Recommended Dilutions:
Western Blot: 1:1000
Immunohistochemistry: 1:50-1:100
Immunocytochemistry: 1:250-1:500
Immunoprecipitation: 1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
TypeIsotypeCloneGrade
MabIgG6k175Supernatant
SizeStorageShippingSourceHost
100ul -20°CBlue IceHumanRabbit
Concentration:
Not Determined
Immunogen:
A synthetic peptide corresponding to residues in human FAK.
Purity:
Supernatant
Form
Supplied as a liquid in 50mM Tris-Glycine, pH7 .4, 0.15M sodium chloride, 0.05% BSA, 0.01% sodium azide,, 40% glycerol.
Specificity:
Recognizes human FAK at ~125kD. Species Crossreactivity: mouse and rat
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schaller, M.D. Biochim. Biophys. Acta 1540: 1–21(2001).2. Schaller, M.D., Borgman, C.A., Cobb, B.S., Vines, R.R., Reynolds, A.B. and Parsons, J.T. Proc. Natl. Acad. Sci. U.S.A. 89: 5192–5196(1992)3. Salazar, E.P. and Rozengurt, E. J. Biol. Chem. 274:28371–28378 (1999).4. Tremblay L., Hauck W., Aprikian A. G., Begin L. R., Chapdelaine A., Chevalier S. Int. J. Cancer, 68: 164-171, (1996)5. Owens L. V., Xu L. H., Craven R. J., Dent G. A., Weiner T. M., Kornberg L., Liu E. T., Cance W. G. Cancer Res., 55: 2752-2755, (1995).